List of questions: Day 120 questions and Day 180 outstanding issues
The list of questions (LoQ) is the CHMP's consolidated set of objections and concerns on a centralised application, adopted at Day 120 of the assessment.
Also known as: LoQ, Day 120 list of questions, list of outstanding issues, LoOI
4 min readUpdated
Reviewed by Gosia Luksza, CEO at Regunaut
At a glance
- Adopted
- Day 120 (list of questions) and Day 180 (list of outstanding issues)
- Response time
- Three months at Day 120, one month at Day 180
- Contains
- Major objections and other concerns on quality, non-clinical, clinical and product information
- Legal basis
- Article 7(c) of Regulation (EC) No 726/2004
How it works
In the centralised procedure the CHMP sends the applicant its questions in two rounds. The list of questions is adopted at Day 120 and the list of outstanding issues at Day 180, and each stops the clock under Article 7(c) of Regulation (EC) No 726/2004 while the applicant responds. The Day 120 list is built from the assessment reports the rapporteur and co-rapporteur circulate at about Day 80, the PRAC rapporteur's assessment of the risk management plan, comments from other committee members and the peer review. It arrives with the committee's overall conclusions, and by Day 120 at the latest the CHMP also adopts any request for a GMP, GLP or GCP inspection.
Questions are sorted into major objections and other concerns, across quality, non-clinical and clinical data, the risk management plan and the product information. A major objection is one that prevents the committee from adopting a positive opinion unless it is resolved. Other concerns still need an answer. After the list is issued the applicant can ask for a clarification meeting with the rapporteurs and EMA, to understand the reasoning behind the major objections and discuss its response strategy; the meeting is not a pre-assessment of the answers.
The response is due within three months and restarts the clock at Day 121. It includes revised English texts of the summary of product characteristics, labelling and package leaflet. The CHMP's rules say that substantial data from new studies should not be introduced unless the committee asked for them, although new analyses and follow-up data from studies already submitted are acceptable. The rapporteurs circulate a joint assessment of the responses at Day 157. If issues remain, the list of outstanding issues follows at Day 180, with one month to respond and room for only very limited new data. Where major objections are still open, the applicant is invited to an oral explanation before the opinion at Day 210.
Under accelerated assessment the same two lists come at Day 90 and Day 120. The decentralised procedure has its own equivalents: the consolidated request for supplementary information at Day 105 and the outstanding issues sent to the applicant around Day 150.
What goes wrong
Answering the wording of a question rather than the concern behind it, so the same major objection returns at Day 180; using the clock-stop to run new studies the committee did not request; updating one module and leaving the summaries and product information inconsistent with it; leaving the comments on the product information to the end; and assuming an extension will be granted, when the CHMP agrees to them only exceptionally.
Timing
Day 80
Rapporteur and co-rapporteur circulate their assessment reports.
Day 120
CHMP adopts the list of questions; clock stops for up to three months.
Day 121
Applicant submits responses and revised product information; clock restarts.
Day 157
Joint assessment report on the responses.
Day 180
List of outstanding issues, if needed; clock stops for one month.
Day 181
Written responses or oral explanation; clock restarts.
By Day 210
CHMP opinion.
The rapporteurs' reports reach the CHMP by about Day 80 and the draft list is circulated at about Day 112. The CHMP adopts the list of questions at Day 120 and the clock stops, for three months by default. Responses restart the clock at Day 121, the joint assessment of the responses is circulated at Day 157, and the list of outstanding issues is adopted at Day 180 with a one-month clock-stop. Responses, and any oral explanation, restart the clock at Day 181, and the opinion follows by Day 210.
What teams do with it in Regunaut
One job in the platform that turn on List of questions, each part of a wider workflow.
What the 2026 EU pharma package changes
Under the new pharma package (not yet in force), the CHMP opinion is due within 180 days instead of 210, with the clock still suspended while the applicant answers, and the CHMP can stop the assessment of a dossier it finds immature within 90 days of validation; see the new pharmaceutical regulation.
List of questions: common questions
What is the difference between a major objection and an other concern?
A major objection prevents the CHMP from adopting a positive opinion unless it is resolved, so every one must be closed before Day 210, if necessary at an oral explanation. Other concerns are points the committee wants answered or corrected but that would not on their own block approval. Both appear in the Day 120 list of questions.
How long do applicants have to respond to the Day 120 list of questions?
Three months. The applicant can request one further period of up to three months by writing to the CHMP chair with a scientific justification, and the committee decides at its next plenary. Extensions beyond six months from the date of the list are not normally accepted. The Day 180 list of outstanding issues allows one month.
Can new data be submitted with the responses?
Only within limits. The CHMP's rules say that, in general, no substantial data from new studies should be introduced in the responses unless the committee specifically requested them. New analyses and follow-up data from studies already in the dossier are acceptable at Day 120. At Day 180 only very limited new data can be assessed.
Sources
- European Medicines Agency: Pre-authorisation guidance for users of the centralised procedure
- European Medicines Agency: Time allowed for applicants to respond to questions and issues raised during the assessment of new marketing authorisation applications in the centralised procedure (EMEA/75401/2006 Rev. 2)
- EUR-Lex: Regulation (EC) No 726/2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use